{
    "Trade/Device Name(s)": [
        "EliA\u2122M Cardiolipin IgA Immunoassay",
        "EliATM Cardiolipin IgA",
        "EliATM APS Positive Control 100",
        "EliATM APS Positive Control 250",
        "EliATM APS IgG/IgM/IgA Negative Control 100",
        "EliATM APS IgG/IgM/IgA Negative Control 250"
    ],
    "Submitter Information": "Phadia AB",
    "510(k) Number": "K131821",
    "Predicate Device Reference 510(k) Number(s)": [],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "MID",
        "JJY"
    ],
    "Summary Letter Date": "November 20, 2013",
    "Summary Letter Received Date": "November 21, 2013",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21CFR866.5660"
    ],
    "Regulation Name(s)": [
        "Multiple autoantibodies immunological test system"
    ],
    "Analyte Class(es)": [
        "autoimmune",
        "immunology"
    ],
    "Analyte(s)": [
        "IgA antibodies to cardiolipin"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma (heparin, EDTA, citrate)"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Phadia 100",
        "Phadia 250"
    ],
    "Method(s)/Technology(ies)": [
        "Fluorescence immunoassay (FIA)",
        "Solid-phase ELISA"
    ],
    "Methodologies": [
        "Immunoassay",
        "Semi-quantitative measurement"
    ],
    "Submission Type(s)": [
        "Assay",
        "Control",
        "Calibrator",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for EliA Cardiolipin IgA immunoassay for detection of IgA autoantibodies to cardiolipin using fluorescence immunoassay on Phadia analyzers.",
    "Indications for Use Summary": "For the in vitro semi-quantitative measurement of IgA antibodies to cardiolipin in serum and plasma to aid in diagnosis of antiphospholipid syndrome (APS) and thrombotic disorders related to systemic lupus erythematosus (SLE), used with Phadia 100/250 analyzers.",
    "fda_folder": "Immunology"
}